Chlorpheniramine

Introduction Overview

Generic Name

chlorpheniramine

Brand Name

Aller-Chlor
Allergy Relief (Chlorpheniramine)
Ed-Chlor Ped Jr
Wal-finate
C.P.M.
Chlo-Amine
Chlor-Mal
Chlor-Trimeton
ChlorTan
Ed ChlorPed
Ed-Chlortan
PediaTan
Triaminic Allergy
Chlor-Phenit
Ridramin
Chlor-Al Rel
Chlor-Phen
Chlorphen
Efidac-24 Chlorpheniramine
Chlor-Trimeton Allergy SR
QDALL AR
P-Tann
Chlorpheniramine (Allergy)
Pediox-S
Ed Chlor-Tan
TanaHist-PD
Pharbechlor
Allergy Time
Chlorphen SR

Dosage Form

oral syrup (2 mg/5 mL)
oral tablet (4 mg)
oral tablet, extended release (12 mg)

Drug Class

Antihistamines

Pharmacokinetics

Absorption:
Chlorpheniramine is well absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations typically occur within 1 to 4 hours post-dose, reflecting rapid and efficient absorption. The bioavailability allows for effective systemic exposure contributing to its antihistaminic effects. Absorption can be influenced by gastrointestinal motility and concurrent intake of food; however, food does not significantly affect the extent of absorption, thus dose administration can be with or without meals.

Distribution:
The drug is widely distributed throughout the body, with an apparent volume of distribution indicating significant extravascular tissue penetration. Chlorpheniramine is known to readily cross the blood-brain barrier, contributing to its sedative side effects. It also crosses the placenta and can be excreted in breast milk. Plasma protein binding is moderate, mainly to albumin, influencing its pharmacodynamic effects. The widespread distribution supports its therapeutic efficacy at peripheral histamine H1 receptors.

Metabolism:
Chlorpheniramine undergoes hepatic metabolism primarily via the cytochrome P450 enzyme system, particularly involving CYP2D6 and other isoenzymes. It is extensively metabolized in the liver to inactive metabolites through demethylation and conjugation pathways. This hepatic biotransformation accounts for its elimination and short half-life. Variability in metabolism can occur due to genetic polymorphisms affecting CYP450 enzymes, liver function impairment, or drug–drug interactions.

Elimination:
The elimination half-life of chlorpheniramine ranges approximately from 12 to 43 hours, reflecting both its parent compound and active metabolites. Excretion is predominantly renal, with the majority of the dose eliminated in urine as metabolites, while a smaller fraction is excreted unchanged. Renal impairment can prolong elimination, necessitating dose adjustments. The pharmacokinetic profile supports dosing regimens and informs clinical considerations, especially in special populations and for avoidance of accumulation and toxicity.

Dosage Forms

Available Dosage Forms:
Chlorpheniramine is available in multiple oral formulations to accommodate various patient needs and preferences. These include:
- Oral syrup at a concentration of 2 mg per 5 mL, enabling precise dosing especially for pediatric patients.
- Immediate-release oral tablets of 4 mg strength, suitable for standard dosing in adults and adolescents.
- Extended-release oral tablets with a 12 mg dose, designed for prolonged antihistaminic effect, allowing once or twice daily dosing intervals.

Dosages for Adults and Adolescents:
For allergic rhinitis and symptomatic relief of allergy symptoms, adults and adolescents typically receive 4 mg every 4 to 6 hours. The maximum daily dose usually should not exceed 24 mg for immediate-release formulations. The extended-release 12 mg tablets can be administered once or twice daily, depending on severity and clinical response, providing convenience and improved compliance.

Specific Patient Populations:
Pediatric dosing requires adjustments and often utilizes the oral syrup formulation for accurate measurement. In elderly patients, a lower dose may be advisable due to increased sensitivity and risk of sedation. Patients with renal or hepatic impairment may require dose modifications given altered metabolism and elimination. Use during pregnancy should be under medical supervision due to potential risks, and lactating mothers are advised to avoid use or consult healthcare providers, as chlorpheniramine can be excreted in breast milk and may affect the neonate.

Clinical dosing guidelines emphasize not to exceed 7 consecutive days of therapy without reevaluation, and extended-release tablets should not be crushed or chewed to maintain controlled drug release. Special dosing considerations include avoiding use in very young children without medical advice due to risk of serious adverse events.

Mechanism Of Action

Chlorpheniramine acts primarily as a selective antagonist of peripheral histamine H1 receptors. Histamine H1 receptors, when activated by endogenous histamine, mediate many allergic symptoms including vasodilation, increased vascular permeability, and sensory nerve stimulation leading to itching and sneezing. By competitively binding to these receptors, chlorpheniramine prevents histamine from eliciting its biological effects, thereby alleviating symptoms of allergic reactions.

On a molecular level, chlorpheniramine inhibits the binding of histamine to H1 receptors located on endothelial cells, smooth muscle, and sensory nerve endings. This blockade limits capillary dilation and leakage, reducing edema and erythema, while also decreasing nerve stimulation that causes itching and sneezing reflexes. Unlike some non-selective antihistamines, chlorpheniramine has negligible effects on H2 receptors, which are primarily involved in gastric acid secretion.

Cellular pathways influenced by chlorpheniramine include reduction of intracellular calcium release and prevention of downstream signaling cascades that would otherwise lead to the synthesis of inflammatory mediators. By inhibiting these pathways, chlorpheniramine exerts anti-inflammatory effects beyond simple receptor antagonism, although these are modest compared to corticosteroids.

Clinically, the sedative properties of chlorpheniramine arise from its ability to cross the blood-brain barrier and antagonize central H1 receptors in the brain, leading to CNS depression manifesting as drowsiness and impaired cognition. This distinguishes chlorpheniramine from second-generation antihistamines, which are less lipophilic and do not readily penetrate the CNS, resulting in fewer sedative effects.

Compared to similar first-generation antihistamines such as diphenhydramine, chlorpheniramine has a slightly longer duration of action and a more favorable side effect profile but shares the risk of anticholinergic effects like dry mouth and urinary retention. Research studies have demonstrated chlorpheniramine’s efficacy in reducing nasal and ocular allergy symptoms in random controlled trials, validating its role as an effective, affordable, and widely used antihistaminic agent.

Pharmacological Actions

Selective competitive antagonist of peripheral histamine H1 receptors, reducing allergic symptoms.
Inhibition of histamine-induced vasodilation and increased capillary permeability.
Reduction of sensory nerve stimulation, thereby decreasing itching, sneezing, and watery eyes.
Crosses the blood-brain barrier to antagonize central H1 receptors, causing sedation.
Exerts mild anticholinergic effects, including drying of mucous membranes.
Moderate oral bioavailability with rapid onset of action within 1 to 4 hours.
Prolonged duration of effect when administered as extended-release formulation.
Metabolized hepatically via cytochrome P450 enzymes, primarily CYP2D6.
Renally eliminated as metabolites and unchanged drug.
Demonstrated efficacy in alleviating symptoms of allergic rhinitis and common cold.
Provides relief from urticaria through histamine receptor blockade.
Mild anti-inflammatory properties secondary to inhibition of histamine pathways.
Used in combination with other agents for comprehensive management of allergic reactions.
Potential CNS depressant effects especially when combined with alcohol or other sedatives.
Ability to reduce nasal congestion indirectly by decreasing histamine-mediated inflammation.

Therapeutic Or Clinical Uses

Treatment of allergic rhinitis symptoms such as sneezing, runny nose, and nasal itching.
Relief of conjunctival symptoms including watery, itchy, or red eyes associated with allergies.
Management of urticaria (hives) and other cutaneous allergic reactions.
Symptomatic relief of common cold symptoms including rhinorrhea and nasal congestion.
Mitigation of itching and discomfort from insect bites or other minor allergic skin conditions.
Adjunct therapy in allergic reactions including anaphylaxis for histamine-related symptoms.
Prevention of allergic responses in sensitive individuals through regular dosing.
Temporary relief of hay fever and seasonal allergy manifestations.
Use in combination with decongestants or analgesics in multi-symptom cold and allergy preparations.
Treatment of allergic manifestations caused by exposure to airborne allergens, dust mites, or pet dander.
Short-term use in cough and cold syndromes due to its anticholinergic effects reducing secretions.
Pediatric use under guidance for allergic symptom management in children.
Supportive therapy for allergic conjunctivitis patients not responding to topical agents.
Off-label uses include treatment of certain pruritic dermatoses and reactions to drug allergies.
Use in preoperative settings to reduce histamine-related reactions during anesthesia.

Side Or Adverse Effects

Sedation and drowsiness due to central histamine H1 receptor antagonism.
Dizziness and impaired cognitive function affecting alertness and coordination.
Dry mouth, nose, and throat as a result of anticholinergic activity.
Constipation due to reduced gastrointestinal motility.
Blurred vision secondary to anticholinergic effects on ocular accommodation.
Nervousness, restlessness, or paradoxical excitation in some cases, especially in children.
Potential for mood changes, tremors, or seizures in rare, severe adverse reactions.
Tachycardia or palpitations reported with overdose or sensitivity.
Easy bruising or abnormal bleeding, possibly related to platelet function interference.
Urinary retention, especially in patients with underlying prostatic hypertrophy.
Shortness of breath or respiratory difficulties in susceptible individuals.
Allergic reactions to chlorpheniramine itself, such as rash, hives, or angioedema.
Photosensitivity reactions documented but uncommon.
Gastrointestinal disturbances including nausea, vomiting, or anorexia.
Potential exacerbation of glaucoma or increased intraocular pressure.

Precautions

Avoid use in patients with narrow-angle glaucoma due to risk of increased intraocular pressure.
Caution in patients with urinary retention or enlarged prostate as anticholinergic effects may worsen symptoms.
Use carefully in individuals with gastrointestinal obstruction or bowel motility disorders.
Monitor patients with asthma or chronic obstructive pulmonary disease as drying secretions may thicken mucus.
Exercise caution in patients with cardiovascular disease or recent myocardial infarction.
Dose adjustments or avoidance recommended in hepatic or renal impairment due to altered metabolism and clearance.
Not recommended for use beyond 7 days without medical evaluation to prevent masking of worsening conditions.
Use with care in elderly patients prone to CNS depression and falls.
Advise patients about possible sedation and impaired mental status; caution driving or operating machinery.
Avoid concurrent use with other CNS depressants, including alcohol, benzodiazepines, and opioids.
Patients with seizure disorders should be monitored since chlorpheniramine may lower seizure threshold.
Do not administer cough or cold preparations containing chlorpheniramine to children under medical supervision.
Pregnant and lactating women should use only under strict medical advice due to potential fetal/neonatal risks.
Patients with phenylketonuria (PKU) should verify absence of phenylalanine in formulations.
Advise hydration and avoidance of overheating because of impaired sweating and increased risk of heat stroke.

Warnings

Avoid use in children without explicit medical guidance due to risk of fatal overdose and severe adverse effects.
Contraindicated with narrow-angle glaucoma or current urinary retention due to worsening risks.
May exacerbate symptoms of prostatic hypertrophy and intestinal obstruction.
Risk of serious CNS depression, including excessive sedation and respiratory depression, especially with other sedative agents.
Potential for anticholinergic toxicity with overdose, leading to confusion, hallucinations, and cardiac arrhythmias.
Sudden discontinuation after prolonged use may precipitate rebound symptoms.
Patients predisposed to seizures should avoid or use with caution, as chlorpheniramine may provoke convulsions.
May impair mental and physical abilities; warnings against driving or operating heavy machinery.
Avoid alcohol consumption during therapy to prevent potentiation of sedative effects.
Use during pregnancy only if benefits outweigh risks, as categorized by FDA as pregnancy category B.
Breastfeeding mothers should avoid use or consult healthcare provider due to possible neonatal effects.
Potential interactions with numerous drugs necessitate thorough medication history to prevent adverse interactions.
Risk of heat stroke due to decreased sweating in hot environments and during exercise.
May cause allergic hypersensitivity reactions including anaphylaxis in rare instances.
Use caution in patients with pre-existing cardiovascular or hepatic disease.

Contraindication

Known allergy or hypersensitivity to chlorpheniramine or any of its components.
Narrow-angle glaucoma due to risk of increased intraocular pressure.
Obstruction of the gastrointestinal tract, including pyloroduodenal or intestinal obstruction.
Presence of urinary retention or significant prostatic hypertrophy contraindicating anticholinergic agents.
Patients currently experiencing an acute asthma attack, where drying of secretions may be harmful.
Use in patients with known hypersensitivity to other antihistamines with similar chemical structures.
Avoid in newborns or premature infants due to increased risk of anticholinergic toxicity.
Known severe hepatic or renal impairment without specialist supervision.
Concurrent use with monoamine oxidase inhibitors (MAOIs) unless under strict medical supervision.
Use contraindicated in patients with phenylketonuria when dosage form contains phenylalanine.
Severe cardiovascular disease patients where sedative or anticholinergic effects may exacerbate condition.
Patients with seizure disorders unless benefits justify risks.
Not recommended in children less than 2 years old without explicit physician direction.
Should not be used with other central nervous system depressants without medical advice.
Known hypersensitivity to any inactive ingredients in formulations.

Drug Interactions

Additive sedative effects when combined with central nervous system depressants such as benzodiazepines, opioids, barbiturates, and alcohol.
Increased anticholinergic side effects when taken with other anticholinergic drugs including tricyclic antidepressants and antipsychotics.
Potential pharmacokinetic interactions via CYP450 enzymes, particularly CYP2D6 inhibitors which may elevate chlorpheniramine plasma levels.
Reduced effectiveness with concomitant use of sympathomimetic agents due to opposing autonomic effects.
Possible enhancement of adverse cardiovascular effects when used with monoamine oxidase inhibitors (MAOIs).
Concurrent use with other antihistamines may lead to excessive anticholinergic and sedative side effects.
Drugs that impair hepatic metabolism or alter renal excretion may affect chlorpheniramine clearance and toxicity risk.
Use with caution alongside seizure threshold lowering agents such as bupropion or theophylline.
Combining with muscle relaxants may potentiate CNS depression and impairment of motor skills.
May interfere with certain diagnostic tests due to anticholinergic properties.
Avoid coadministration with drugs that increase intraocular pressure due to risk of exacerbated glaucoma.
Concomitant use with sedative hypnotics may complicate postoperative recovery and respiratory function.
Potential decreased efficacy when used with barbiturates that induce hepatic enzymes.
Additive cognitive impairment with psychoactive drugs including antidepressants and antipsychotics.
Pharmacodynamic interactions with drugs affecting autonomic nervous system function may unpredictably alter blood pressure and heart rate.

Preparations Of The Drug

Oral syrup containing 2 mg chlorpheniramine per 5 mL, sweetened and flavored for pediatric use.
Immediate-release oral tablets in 4 mg strength for standard symptomatic relief dosing.
Extended-release oral tablets of 12 mg designed for once or twice daily administration.
Combination products containing chlorpheniramine with decongestants, analgesics, or antitussives for multi-symptom cold and allergy relief.
Pediatric formulations featuring reduced concentrations and dosing devices for accurate administration.
Over-the-counter availability in many formulations, facilitating accessibility for allergic symptom management.
Pharmaceutical preparations may include film-coated tablets to mask bitter taste and improve compliance.
Liquid formulations may contain artificial sweeteners; phenylalanine content should be checked for patients with PKU.
Some formulations include chlorpheniramine in sustained-release matrix tablets to prolong therapeutic effect.
Packaging designed for moisture protection and stability, typically in blister packs or plastic bottles.
Available as generic formulations and multiple brand names to enhance patient choice and insurance coverage.
Topical preparations are not commonly available; chlorpheniramine use is primarily systemic.
Prepared in preservative-containing or preservative-free formulations to accommodate patients with sensitivities.
Some extended-release preparations should not be crushed or chewed to maintain pharmacokinetic profile.
Pharmaceutical grade chlorpheniramine adheres to regulatory standards ensuring safety, efficacy, and quality control.